Ansari Leyla, Nasiri Neda, Aminolroayaei Fahimeh, Sani Karim Ghazikhanlou, Dorri-Giv Masoumeh, Abedi-Firouzjah Razzagh, Sardari Dariush
Department of Radiation Sciences, Faculty of Paramedicine, Yasuj University of Medical Science, Yasuj, Iran.
Department of Medical Radiation Engineering, Science and Research Branch, Islamic Azad University, Tehran, Iran.
J Med Signals Sens. 2020 Feb 6;10(1):42-47. doi: 10.4103/jmss.JMSS_10_19. eCollection 2020 Jan-Mar.
Radiotherapy is a main method for the treatment of breast cancer. This study aimed to measure the absorbed dose of thyroid gland using Gafchromic EBT2 film during breast cancer radiotherapy. In addition, the relationship between the absorbed dose and thyroid hormone levels was evaluated.
Forty-six breast cancer patients, with the age ranged between 25 and 35 years, undergoing external radiotherapy were studied. The patients were treated with 6 and 18 MV X-ray beams, and the absorbed thyroid dose was measured by EBT2 film. Thyroid hormone levels, thyroid-stimulating hormone (TSH), triiodothyronine (T3), and thyroxin (T4), were measured before and after the radiotherapy. Pearson's, Spearman's, and Chi-square tests were performed to evaluate the correlation between the thyroid dose and hormone levels.
The mean thyroid dose was 26 ± 9.45 cGy with the range of 7.85-48.35 cGy. There were not any significant differences at thyroid hormone levels between preradiotherapy and postradiotherapy ( > 0.05). There was a significant relationship between increased thyroid absorbed dose and changes in TSH and T4 levels ( < 0.05), but it was not significant in T3 level ( = 0.1).
Regarding the results, the thyroid absorbed dose can have an effect on its function. Therefore, the thyroid gland should be considered as an organ at risk in breast cancer radiotherapy.
放射治疗是乳腺癌治疗的主要方法。本研究旨在使用Gafchromic EBT2胶片测量乳腺癌放疗期间甲状腺的吸收剂量。此外,还评估了吸收剂量与甲状腺激素水平之间的关系。
对46例年龄在25至35岁之间接受外照射放疗的乳腺癌患者进行研究。患者接受6和18兆伏X射线束治疗,并用EBT2胶片测量甲状腺吸收剂量。在放疗前后测量甲状腺激素水平,即促甲状腺激素(TSH)、三碘甲状腺原氨酸(T3)和甲状腺素(T4)。进行Pearson检验、Spearman检验和卡方检验以评估甲状腺剂量与激素水平之间的相关性。
甲状腺平均剂量为26±9.45厘戈瑞,范围为7.85 - 48.35厘戈瑞。放疗前和放疗后甲状腺激素水平无显著差异(>0.05)。甲状腺吸收剂量增加与TSH和T4水平变化之间存在显著关系(<0.05),但在T3水平上不显著(=0.1)。
根据研究结果,甲状腺吸收剂量可能会对其功能产生影响。因此,在乳腺癌放疗中应将甲状腺视为危险器官。